Kristie A Blum1,2, Mei-Yin Polley3, Sin-Ho Jung4, Travis J Dockter3, Sarah Anderson3, Eric D Hsi5, Nina Wagner-Johnston6, Beth Christian2, Jim Atkins7, Bruce D Cheson8, John P Leonard9, Nancy L Bartlett6. 1. Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. 2. Comprehensive Cancer Center, Ohio State University, Columbus, Ohio. 3. Alliance Statistics and Data Center, Mayo Clinic College of Medicine, Rochester, Minnesota. 4. Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina. 5. Department of Clinical Pathology, Cleveland Clinic, Cleveland, Ohio. 6. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri. 7. Southeast Clinical Oncology Research Consortium, NCI Community Oncology Research Program, Winston-Salem, North Carolina. 8. Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC. 9. Department of Medicine and Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
Abstract
BACKGROUND: This multicenter, randomized phase 2 trial evaluated complete responses (CRs), efficacy, and safety with ofatumumab and bendamustine and with ofatumumab, bendamustine, and bortezomib in patients with untreated, high-risk follicular lymphoma (FL). METHODS:Patients with grade 1 to 3a FL and either a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 with 1 lymph node >6 cm or an FLIPI score of 3 to 5 were randomized toarm A (ofatumumab, bendamustine, and maintenance ofatumumab) or to arm B (ofatumumab, bendamustine, bortezomib, and maintenance ofatumumab and bortezomib). RESULTS:One hundred twenty-eight patients (66 in arm A and 62 in arm B) received treatment. The median age was 61 years, and 61% had disease >6 cm; 29% had an FLIPI score of 2, and 71% had an FLIPI score of 3 to 5. In arm A, 86% completed induction, and 64% completed maintenance. In arm B, 66% and 52% completed induction and maintenance, respectively. Dose modifications were required in 65% and 89% in arms A and B, respectively. Clinically significant grade 3 to 4 toxicities included neutropenia (A, 36%; B, 31%), nausea/vomiting (A, 0%; B, 8%), diarrhea (A, 5%; B, 11%), and sensory neuropathy (A, 0%; B, 5%). The estimated CR rates were 62% (95% confidence interval [CI], 50%-74%) and 60% (95% CI, 47%-72%) in arms A and B, respectively (P = .68). With a median follow-up of 3.3 years, the estimated 2-year progression-free survival (PFS) and overall survival (OS) rates were 80% and 97%, respectively, for arm A and 76% and 91%, respectively, for arm B. CONCLUSIONS: The CR rates, PFS, and OS were not improved with the addition of bortezomib to ofatumumab and bendamustine in patients with high-risk FL. Although grade 3 to 4 toxicities were similar, more patients treated with bortezomib required dose modifications and early discontinuation.
RCT Entities:
BACKGROUND: This multicenter, randomized phase 2 trial evaluated complete responses (CRs), efficacy, and safety with ofatumumab and bendamustine and with ofatumumab, bendamustine, and bortezomib in patients with untreated, high-risk follicular lymphoma (FL). METHODS:Patients with grade 1 to 3a FL and either a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 with 1 lymph node >6 cm or an FLIPI score of 3 to 5 were randomized to arm A (ofatumumab, bendamustine, and maintenance ofatumumab) or to arm B (ofatumumab, bendamustine, bortezomib, and maintenance ofatumumab and bortezomib). RESULTS: One hundred twenty-eight patients (66 in arm A and 62 in arm B) received treatment. The median age was 61 years, and 61% had disease >6 cm; 29% had an FLIPI score of 2, and 71% had an FLIPI score of 3 to 5. In arm A, 86% completed induction, and 64% completed maintenance. In arm B, 66% and 52% completed induction and maintenance, respectively. Dose modifications were required in 65% and 89% in arms A and B, respectively. Clinically significant grade 3 to 4 toxicities included neutropenia (A, 36%; B, 31%), nausea/vomiting (A, 0%; B, 8%), diarrhea (A, 5%; B, 11%), and sensory neuropathy (A, 0%; B, 5%). The estimated CR rates were 62% (95% confidence interval [CI], 50%-74%) and 60% (95% CI, 47%-72%) in arms A and B, respectively (P = .68). With a median follow-up of 3.3 years, the estimated 2-year progression-free survival (PFS) and overall survival (OS) rates were 80% and 97%, respectively, for arm A and 76% and 91%, respectively, for arm B. CONCLUSIONS: The CR rates, PFS, and OS were not improved with the addition of bortezomib to ofatumumab and bendamustine in patients with high-risk FL. Although grade 3 to 4 toxicities were similar, more patients treated with bortezomib required dose modifications and early discontinuation.
Authors: Myron S Czuczman; Georg Hess; Ole V Gadeberg; Lars M Pedersen; Nancy Goldstein; Ira Gupta; Roxanne C Jewell; Thomas S Lin; Steen Lisby; Claus Strange; Kristian Windfeld; Andreas Viardot Journal: Br J Haematol Date: 2012-03-13 Impact factor: 6.998
Authors: Nathan Fowler; Brad S Kahl; Peter Lee; Jeffrey V Matous; Amanda F Cashen; Samuel A Jacobs; Jeffrey Letzer; Bipinkumar Amin; Michael E Williams; Sonali Smith; Alfred Saleh; Peter Rosen; Hongliang Shi; Sudha Parasuraman; Bruce D Cheson Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: Laurie H Sehn; David MacDonald; Sheldon Rubin; Guy Cantin; Morel Rubinger; Bernard Lemieux; Sanraj Basi; Kevin Imrie; Randy D Gascoyne; Jonathan Sussman; Bingshu E Chen; Marina Djurfeldt; Lois Shepherd; Stephen Couban; Michael Crump Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: Mathias J Rummel; Norbert Niederle; Georg Maschmeyer; G Andre Banat; Ulrich von Grünhagen; Christoph Losem; Dorothea Kofahl-Krause; Gerhard Heil; Manfred Welslau; Christina Balser; Ulrich Kaiser; Eckhart Weidmann; Heinz Dürk; Harald Ballo; Martina Stauch; Fritz Roller; Juergen Barth; Dieter Hoelzer; Axel Hinke; Wolfram Brugger Journal: Lancet Date: 2013-02-20 Impact factor: 79.321
Authors: Myron S Czuczman; Luis Fayad; Vincent Delwail; Guillaume Cartron; Eric Jacobsen; Kazimierz Kuliczkowski; Brian K Link; Lauren Pinter-Brown; John Radford; Andrzej Hellmann; Eve Gallop-Evans; Christine G DiRienzo; Nancy Goldstein; Ira Gupta; Roxanne C Jewell; Thomas S Lin; Steen Lisby; Martin Schultz; Charlotte A Russell; Anton Hagenbeek Journal: Blood Date: 2012-03-02 Impact factor: 22.113
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Jonathan W Friedberg; Julie M Vose; Jennifer L Kelly; Faith Young; Steven H Bernstein; Derick Peterson; Lynn Rich; Susan Blumel; Nicole K Proia; Jane Liesveld; Richard I Fisher; James O Armitage; Steven Grant; John P Leonard Journal: Blood Date: 2011-01-14 Impact factor: 22.113
Authors: Massimo Federico; Monica Bellei; Luigi Marcheselli; Stefano Luminari; Armando Lopez-Guillermo; Umberto Vitolo; Barbara Pro; Stefano Pileri; Alessandro Pulsoni; Pierre Soubeyran; Sergio Cortelazzo; Giovanni Martinelli; Maurizio Martelli; Luigi Rigacci; Luca Arcaini; Francesco Di Raimondo; Francesco Merli; Elena Sabattini; Peter McLaughlin; Philippe Solal-Céligny Journal: J Clin Oncol Date: 2009-08-03 Impact factor: 44.544
Authors: Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat Journal: Blood Date: 2004-05-04 Impact factor: 22.113